|1.||Fujiwara, Michihiro: 3 articles (01/2008 - 01/2006)|
|2.||Iwasaki, Katsunori: 3 articles (01/2008 - 01/2006)|
|3.||Mishima, Kenichi: 3 articles (01/2008 - 01/2006)|
|4.||Egashira, Nobuaki: 3 articles (01/2008 - 01/2006)|
|5.||Kurauchi, Kouji: 2 articles (01/2008 - 02/2007)|
|6.||Shoyama, Yukihiro: 2 articles (02/2007 - 01/2006)|
|7.||Matsumoto, Yoshiaki: 2 articles (02/2007 - 01/2006)|
|8.||Viana, G S B: 2 articles (09/2005 - 03/2002)|
|9.||Pinguet, Jérémy: 1 article (12/2015)|
|10.||Graveron-Demilly, Danielle: 1 article (12/2015)|
09/16/2005 - "LEV (LEV200, 200 mg/kg, i.p.) pretreatment also reduced the intensity of tremors induced by oxotremorine (0.5 mg/kg, i.p). "
07/15/2004 - "The effects of oxotremorine (OXO) on autonomic functions and tremor were examined in mice lacking alpha5 nAChR subunits (alpha5-/-) and compared with those in wild-type (WT) control mice. "
04/01/2003 - "Oxotremorine-induced tremor was abolished only in the M2 knockout mice. "
04/01/2000 - "The action of Ola on apomorpine (Apo)-induced climbing behavior, 5-hydroxy-dl-tryptophan (5-HTP)-induced head twitch response, oxotremorine-induced tremor, and the conditioned avoidance behavior in mice were observed. "
10/01/1999 - "Intensity of the tremor was classified into 7 degrees, and it was evaluated every 10 min. The total intensity of oxotremorine-induced tremor for each drug was expressed as "points", which were the sum of tremor intensity scores evaluated every 10 min up to 190 min following the administration of oxotremorine. "
|2.||Parkinson Disease (Parkinson's Disease)
04/29/1977 - "LON 954 appears to be more specific than oxotremorine for the detection of drugs having therapeutic potential in the treatment of Parkinson's disease, particularly those exerting their effect through dopaminergic systems. "
03/01/1973 - "The relative activity assessed by the inhibition of pilocarpine-induced salivation was 0.13 after oral administration and 0.056 following subcutaneous administration of the drugs.3. Benapryzine had the same order of activity as benzhexol in inhibiting oxotremorine-induced tremors in mice.4. Benapryzine had anticonvulsant properties but no analgesic activity, whilst in high doses it antagonized the extrapyramidal symptoms induced by perphenazine in rats.5. In patients benapryzine was effective in reducing the symptoms of Parkinson's disease without overt anti-cholinergic effects or central hallucinogenic actions.6. Benapryzine abolished the excess tremor and reduced the rigidity and akinesia induced by physostigmine in Parkinsonian subjects."
|3.||Memory Disorders (Memory Loss)
07/11/1996 - "Oral administration of AF102B and oxotremorine improved scopolamine-induced memory deficits in a passive avoidance task in mice at doses of 1.0 mg/kg and 0.2 mg/kg, respectively. "
02/01/2010 - "The effects of a single administration of the acetylcholinesterase (AChE) inhibitor galantamine or the muscarinic receptor agonist oxotremorine on iron-induced memory deficits in rats were examined. "
|4.||Alzheimer Disease (Alzheimer's Disease)
04/01/1987 - "Induction of depression with oxotremorine in patients with Alzheimer's disease."
04/01/1987 - "In this study seven patients with Alzheimer's disease were given oral oxotremorine, a long-acting cholinergic agonist, to assess the drug's effects on cognitive function. "
11/01/1986 - "Physostigmine, oxotremorine, RS-86, and a combination of piracetam and lecithin, have all been studied in patients with Alzheimer's disease. "
12/01/1989 - "Clinical experience with muscarinic agonists in the symptomatic treatment of Alzheimer's disease includes studies of the effects of pilocarpine, arecoline, bethanechol, oxotremorine and RS 86. "
10/17/1994 - "In the present study, the electrolytic lesions of AV3V region significantly inhibited oxotremorine-induced increases in both blood pressure and survival rate in rats subjected to hemorrhagic shock. "
10/05/2001 - "The role of nitric oxide in the reversal of hemorrhagic shock by oxotremorine."
10/17/1994 - "These results indicate that oxotremorine-induced pressor response and decrease in mortality in rats with severe hemorrhagic shock are primarily mediated via central muscarinic and nicotinic receptors, respectively. "
10/17/1994 - "Reversal of hemorrhagic shock in rats by oxotremorine: the role of muscarinic and nicotinic receptors, and AV3V region."
10/05/2001 - "In the present study, the effect of the nitric oxide synthase inhibitor, N(G)-nitro-L-arginine methylester (L-NAME), on the antishock actions of oxotremorine was investigated in rats subjected to hemorrhagic shock under urethane anesthesia. "
|6.||K 351 (nipradilol)